Automatic Website Traffic RSS
Arrowhead Pharmaceuticals Finally Another Buying Opportunity | AutoTraffic
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
Despite the CRL setback and heavy dilution, we remain optimistic on etripamil’s long-term market potential and Milestone’s investment thesis. The recent $52.5 million equity raise was poorly timed and ...
read more Sarepta sells Arrowhead stock, activates $100M milestone payment
Sarepta Therapeutics (NASDAQ:SRPT) has announced the sale of about 9.3M shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a private block trade, anticipating gross proceeds of at least $174M.
read more Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks
July 23 (Reuters) - Sarepta Therapeutics' (SRPT.O), opens new tab licensing partner Arrowhead Pharmaceuticals (ARWR.O), opens new tab said on Wednesday it expects to receive near-term milestone ...
read more 
Subscribe to RSS Feed
